DocuSign: Is There a Reason Not to Buy? Here's What Traders Can Do Now

This was not a bad quarter. The increased buyback is nice. Cash flows are impressive. The balance sheet is not as bad as it looks.

These 3 Biopharma Stocks Look Increasingly Promising

We've delved into some trial updates and technical observations.

Think the Market Correction Is Over? Show Me the Evidence

Here's what's keeping us cautious.

A Cold Hand Heats Up With This Under-the-Radar Stock

Let's see why a shipping stock could prove there's a 'cold hand fallacy' as well.

Tom Lee: Market Tailwinds Should Prevail Later This Month

September is proving to be challenging, but here's why we see probabilities of a better finish to the month. Plus, our top three sector picks.

Honda Is on the Verge of a Major Upside Move

The charts are looking very strong. Here's my longer-term price target.

Don't Spit Into the Wind When Trading Small-Caps and Keep a Close Eye on Banks

The SPDR Select Sector Financial ETF has managed to avoid the same cascade as the iShares Russell 2000 ETF, but it isn't a picture of health, either.

Boston Scientific Is Looking for a Possible Breakout

Its stock price has performed strongly the past 12 months. Can that continue?

Avoid Apple Supplier Qualcomm Until It Builds a Better Base

The chipmaker's stock is feeling the effects of China's edict that employees of government agencies can't use Apple iPhones for work.

Market Blame Game, Apple, China and Huawei, Intel and GlobalFoundries Heat Up

'Who's' to blame for the recent market selloff? Here are the prime suspects.